All lobbying filings

FRESENIUS KABI USA LLC

FRESENIUS KABI USA LLC filed a Q1 report for FRESENIUS KABI USA LLC on May 6, 2025.

Lobbying for FRESENIUS KABI USA LLC

All filings by FRESENIUS KABI USA LLC · Everything FRESENIUS KABI USA LLC has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted May 6, 2025

Expenses

$712,941

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Illinois

Official filing document

Lobbyists on this filing 3

SARAH CHRISTINE D'ORSIE

Previously held: Congressman Tom Davis
TIMOTHY CASEY

Previously held: Congressman John Tierney Senator Tom Carper
STEVEN CHASE WALKER New on this filing

Previously held: Congressman Jodey Arrington

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 10

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 7

Manufacturing

Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launch

Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices

Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, made in America

Pharmacy

PBM reform, including spread pricing, AWP policy, ASP policy

Medicare/Medicaid

PBM reform, patent reform, ASP reform, international reference pricing, IRA Medicare negotiation, inflation penalty

Taxation/Internal Revenue Code

BEAT, AMT, U.S. manufacturing incentives

Health Issues

Drug pricing, PBM Reform, patent reform, biosimilars, generics, medical devices, FDA approvals, DEHP

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.